Breaking News Instant updates and real-time market news.

MRK

Merck

$61.52

-0.62 (-1.00%)

, MRO

Marathon Oil

$14.18

-0.4 (-2.74%)

07:30
10/18/16
10/18
07:30
10/18/16
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Monday in Merck (MRK), Marathon Oil (MRO), Mondelez (MDLZ), Skechers (SKX), Golar LNG (GLNG), Fifth Third (FITB), Infinera (INFN), and Myriad Genetics (MYGN).

MRK

Merck

$61.52

-0.62 (-1.00%)

MRO

Marathon Oil

$14.18

-0.4 (-2.74%)

MDLZ

Mondelez

$41.99

-0.06 (-0.14%)

SKX

Skechers

$22.12

-0.71 (-3.11%)

GLNG

Golar LNG

$22.85

0.4 (1.78%)

FITB

Fifth Third

$19.58

-0.22 (-1.11%)

INFN

Infinera

$8.62

-0.22 (-2.49%)

MYGN

Myriad Genetics

$19.31

0.68 (3.65%)

  • 20

    Oct

  • 20

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 03

    Nov

  • 06

    Nov

MRK Merck
$61.52

-0.62 (-1.00%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
10/13/16
BOFA
10/13/16
UPGRADE
Target $70
BOFA
Buy
Merck upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Colin Bristow upgraded Merck to Buy and raised its price target to $70 from $57 to reflect its opportunity in first line lung cancer. Bristow significantly raised his Keytruda sales estmate to 7.5B from $5.5B following Merck's first line lung cancer data presentations at ESMO over the weekend and feedback from experts. He expects Keytruda to receive early approval/launch in first line NSCLC from the December 24 PDUFA and to become the standard of care in the identified label and further upside from chemo combo.
MRO Marathon Oil
$14.18

-0.4 (-2.74%)

10/17/16
LEHM
10/17/16
DOWNGRADE
Target $17
LEHM
Equal Weight
Marathon Oil downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Thomas Driscoll downgraded Marathon Oil to Equal Weight in a research note previewing Q3 earnings for the Exploration & Production space. The analyst believes a "growth shortfall" relative to peers could lead to the shares underperforming. Driscoll lowered his price target for the shares to $17 from $18.
09/30/16
ADAM
09/30/16
INITIATION
Target $16
ADAM
Hold
Marathon Oil initiated with a Hold at Canaccord
Canaccord analyst Stephen Berman initiated Marathon Oil with a Hold and a $16 price target due to unhedged exposure to oil and gas prices.
09/12/16
09/12/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Reynolds American (RAI) downgraded to Neutral from Buy at Goldman with analyst Judy Hong citing valuation and fading earnings momentum. 2. TrueCar (TRUE) downgraded to Underweight from Equal Weight at Morgan Stanley with analysts led by Brian Nowak citing valuation. 3. Marathon Oil (MRO) downgraded to Neutral from Outperform at Credit Suisse analyst Edward Westlake saying the company has down an excellent job increasing the resource base, lowering well costs, and said the STACK continues to get better, but continues to see more momentum in the purer play Permian names. 4. Whirlpool (WHR) downgraded to Hold from Buy at Gabelli with analyst Alvaro Lacayo saying the substantial rise of steel prices will likely negatively impact North American margins in the short-term. 5. Verifone (PAY) downgraded to In-Line from Outperform at Imperial Capital with analyst Saliq Khan citing a lack of EMV adoption and the challenging macro environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/16
FBCO
09/12/16
DOWNGRADE
Target $19
FBCO
Neutral
Marathon Oil downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Edward Westlake downgraded Marathon Oil to Neutral saying the company has down an excellent job increasing the resource base, lowering well costs, and said the STACK continues to get better, but continues to see more momentum in the purer play Permian names. Westlake maintained his $19 price target on Marathon shares.
MDLZ Mondelez
$41.99

-0.06 (-0.14%)

08/30/16
STFL
08/30/16
NO CHANGE
STFL
No other bidder likely to emerge for Hershey, says Stifel
After Mondolez (MDLZ) announced that it had terminated talks about a potential merger with Hershey (HSY), Stifel analyst Christopher Growe does not expect another bidder for Hershey to emerge. He thinks that potential bidders, including Nestle (NSRGY), will be deterred by the issues that Mondolez encountered. The analyst says that Mondolez's stock could rise to the mid to upper $40s as investors again focus on the possibility of the company combining with Kraft Heinz (HNZ). However, he keeps a Hold rating on Mondolez.
08/30/16
08/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BofA Merrill Lynch resumed coverage on Hershey (HSY) with an Underperform rating and $100 price target, as the firm expects shares to trade on fundamentals, which are under pressure. Last night, Mondelez (MDLZ) announced it has ended discussions with Hershey regarding a possible combination of the two companies. 2. eBay (EBAY) initiated with a Long-Term Buy at Hilliard Lyons by analyst Stephen Turner , who set a $35 price target on the stock. 3. Galapagos NV (GLPG) initiated with a Buy at Janney Capital by Debjit Chattopadhyay, who said that filgotinib, the company's oral JAK inhibitor, is "shaping up to be a blockbuster." 4. Gemphire Therapeutics (GEMP) initiated with with a Buy rating and $17 price target by Canaccord Genuity analyst John Newman and with a Buy rating and $15 price target by Jefferies analyst Matthew Andrews. 5. Sophiris Bio (SPHS) initiated with an an Overweight rating and $7 price target by Piper Jaffray analyst Charles Duncan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/16
JPMS
09/06/16
INITIATION
Target $50
JPMS
Overweight
Mondelez reinstated with an Overweight at JPMorgan
JPMorgan analyst Ken Goldman reinstated Mondelez with an Overweight rating and $50 price target following a period of restriction. The rating is unchanged and the price target is raised from $49.
09/23/16
JPMS
09/23/16
NO CHANGE
JPMS
Neutral
JPMorgan says Mondelez speculation misguided, not pursuing Hershey again
JPMorgan analyst Ken Goldman noted that strength in Hershey (HSY) shares this morning was being attributed to speculation that Mondelez (MDLZ) might be back in talks to buy the company. However, after speaking with Mondelez, the analyst said it is clear that the company's stance is unchanged and there have been no new deal talks, nor does he think there will be any. Goldman keeps a Neutral rating on Hershey shares, which have given up their early gains and turned slightly negative for the session.
SKX Skechers
$22.12

-0.71 (-3.11%)

09/30/16
09/30/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded on potential NXP Semiconductors acquisition at Mizuho with the firm's analyst saying he believes a Qualcomm acquisition of NXP Semiconductors (NXPI) makes significant strategic and financial sense. 2. Skechers (SKX) upgraded to Positive from Neutral at Susquehanna. 3. Sprouts Farmers Markets (SFM) upgraded to Buy from Hold at Jefferies with analyst Christopher Mandeville saying the risk/reward is now favorable following the recent pullback in the shares. 4. Phillips 66 (PSX) upgraded to Neutral from Sell at Goldman with analyst Neil Mehta citing higher multiple assumptions for midstream and chemicals segments, reduced capex spending and higher free cash flow estimates, and more achievable consensus expectations. 5. NetApp (NTAP) upgraded to Buy from Sell at Summit Redstone with analyst Srini Nandury citing optimism that the company can grow its product revenue from current levels driven by AFA sales and increasing adoption of clustered ONTAP. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/16
SUSQ
09/30/16
UPGRADE
SUSQ
Positive
Skechers upgraded to Positive from Neutral at Susquehanna
10/03/16
STPT
10/03/16
INITIATION
Target $30
STPT
Buy
Skechers initiated with a Buy at Standpoint Research
Target $30.
10/13/16
SBSH
10/13/16
NO CHANGE
Target $33
SBSH
Buy
Skechers risk/reward viewed as compelling at Citi
Citi analyst Corinna Van der Ghinst believes shares of Skechers are now pricing in a more bearish view of the U.S. and reduced margin expectations, creating a "compelling" risk/reward profile. The analyst lowered her price target for the shares to $33 from $38 and keeps a Buy rating on the shares. Van der Ghinst is taking a more conservative stance on Skechers' U.S. business citing a "tepid" back-to-school season as well as further discounting on premium competing brands in the mid-tier this fall.
GLNG Golar LNG
$22.85

0.4 (1.78%)

09/07/16
MSCO
09/07/16
NO CHANGE
Target $30
MSCO
Overweight
Morgan Stanley has increased confidence in Golar LNG growth potential
Morgan Stanley analyst Fotis Giannakoulis has increased confidence in Golar LNG's growth potential following the creation of two new joint ventures of Golar Power with Stonepeak and OneFLNG with Schlumberger and the positive commentary on Ophir's Fortuna FLNG. The analyst reiterates his Overweight rating and increased its price target to $30 from $29 on Golar LNG shares.
08/01/16
08/01/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Golar LNG (GLNG) upgraded to Buy from Neutral at BofA/Merrill with analyst Ken Hoexter saying he believes negative news of low LNG rates, delayed new terminals, and potential financing gap are reflected in shares. 2. Coach (COH) upgraded to Positive from Mixed at OTR Global following checks that indicate steady progress by store managers, more appealing offerings, new open-to-the-public Mother's Day sale at full-price Coach stores and tight wholesale distribution. 3. Harley-Davidson (HOG) upgraded to Outperform from Market Perform at BMO Capital with analyst Gerrick Johnson saying the stock provides a good contrarian trading opportunity, given the highly negative sentiment towards it. Over the longer term, the analyst thinks that the company's accelerated development of new products will beat fruit. 4. Dollar Tree upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the Family Dollar acquisition will provide "more upside opportunities." 5. Houghton Mifflin (HMHC) upgraded to Buy from Neutral at Goldman with analyst Andre Benjamin saying the shares can rally on both positive estimate revisions and multiple expansion after underperforming year-to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
ABNA
10/03/16
UPGRADE
ABNA
Hold
Golar LNG upgraded to Hold from Sell at ABN Amro
08/01/16
08/01/16
UPGRADE
Target $21

Buy
Golar LNG upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Ken Hoexter upgraded Golar LNG to Buy and raised its price target to $21 from $19. The analyst believes negative news of low LNG rates, delayed new terminals, and potential financing gap are reflected in shares.
FITB Fifth Third
$19.58

-0.22 (-1.11%)

10/10/16
10/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Honeywell (HON) downgraded to Buy from Conviction Buy at Goldman with analyst Christopher Glynn lowering his Q3 Earnings Per Share expectations for Honeywell after the company cut its earnings and revenue outlook and trimmed his price target to $122 from $128. 2. United Technologies (UTX) downgraded to Neutral from Buy at Citi with analyst Jason Gursky saying he sees three issues limiting share upside over the next twelve-plus months. 3. PNC Financial (PNC) was downgraded to Neutral from Buy at Nomura while the firm downgraded Fifth Third (FITB) to Reduce from Neutral. 4. Myriad Genetics (MYGN) downgraded to Sell from Neutral at Ladenburg with analyst Kevin DeGeeter citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. 5. HSN, Inc. (HSNI) downgraded to Hold from Buy at Craig-Hallum with analyst Alex Fuhrman saying his channel checks indicate continued weakness in the third quarter, with particular weakness in jewelry and consumer electronics. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
10/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tyson Foods (TSN) downgraded to Sell from Hold at Pivotal Research with analyst Timothy Ramey citing the broiler price-fixing alleged in the class action complaint filed on September 2. 2. SolarEdge (SEDG) was downgraded to Sell from Neutral at Goldman while the firm also downgraded First Solar (FSLR) to Neutral from Buy. 3. CIT Group (CIT) downgraded to Hold from Buy at Stifel with analyst Christopher Brendler saying investors should sell into the rally that will result from the "impressive" price that the company received for its aircraft business and the approval of its capital plan by the Fed. 4. Fifth Third (FITB) downgraded to Hold from Buy at Jefferies with analyst Ken Usdin saying the shares are reasonably valued following the recent rally. 5. Blackhawk (HAWK) downgraded to Neutral from Buy at BofA/Merrill with analyst David Chu saying the firm's channel checks indicate that conversions to EMV, the new standard for chip-based debit/credit card transactions, are taking longer than expected, which he believes could impact Blackhawk's 2016 guidance and expectations for 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
10/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zillow (ZG, Z) initiated with a Buy at Needham. 2. AMD (AMD) initiated with an Equal Weight at Barclays. 3. Aflac (AFL) was initiated with an Underperform at Credit Suisse while the firm also initiated Prudential (PRU) and Assurant (AIZ) with a Neutral. 4. Fifth Third (FITB) initiated with a Neutral at Wedbush. 5. GW Pharmaceuticals (GWPH) initiated with a Buy at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/16
NOMU
10/10/16
DOWNGRADE
Target $16
NOMU
Reduce
Fifth Third downgraded to Reduce from Neutral at Nomura
Nomura analyst Bill Carcache downgraded Fifth Third to Reduce and maintained its $16 price target. The analyst expects shares to underperform due to a combination of disappointing loan growth, securities reinvestment headwinds, and negative earnings revisions.
INFN Infinera
$8.62

-0.22 (-2.49%)

10/11/16
GSCO
10/11/16
DOWNGRADE
Target $36
GSCO
Sell
Lumentum downgraded to Sell from Neutral at Goldman
Goldman Sachs analyst Doug Clark downgraded Lumentum (LITE) to Sell saying product substitution and competition are risks to the company's "premium" valuation. Lumentum is slightly behind competitors in terms of timing of new product ramp, Clark tells investors in a research note. His $36 price target represents 19% downside. The analyst this morning also upgraded Finisar (FNSR) to Buy and kept Neutral ratings on Acacia Communications (ACIA) and Infinera (INFN) in a research note on the Optical Components space.
08/25/16
SBSH
08/25/16
NO CHANGE
Target $23
SBSH
Neutral
Ciena Q3 results should be relatively in-line, says Citi
Citi analyst Stanley Kovler raised his price target on Ciena (CIEN) to $23 from $21, saying that he expects a relatively in-line Q3 report from the company. He also removed the firm's High Risk rating on Ciena due to lower share volatility, but keeps a Neutral rating on the shares, saying that Infinera's (INFN) aggressive pricing in Ciena's metro markets outside of Tier 1, along with existing pricing pressure from other players, is a major risk going forward.
08/25/16
08/25/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Northrop Grumman (NOC) downgraded to Neutral from Overweight at JPMorgan with analyst Seth Seifman saying he recommends taking profits on shares and said cash flow estimates are below consensus due to capex projections. 2. Sprint (S) downgraded to Underperform from Neutral at Buckingham with analyst James Ratcliffe saying shares are more than pricing in continued improvement in subscriber and ARPU performance, along with capex at or below industry norms at current levels. 3. DHT Holdings (DHT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Fotis Giannakoulis saying he expects crude tanker demand to lag fleet supply in 2017-2018 and sees potential pressure on the dividend. 4. Workday (WDAY) downgraded to Equal-Weight from Overweight at First Analysis with analyst Corey Greendale saying the company's second quarter results beat expectations but lowered its rating due to valuation. 5. Infinera (INFN) downgraded to Sell from Neutral at Citi with analyst Stanley Kovler saying he expects additional margin pressure from Research and Development spending and its "aggressive" pursuit of Metro deals translating into "yet another leg down" in the company's earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/16
STFL
09/30/16
INITIATION
STFL
Hold
Infinera coverage resumed with a Hold at Stifel
Analyst PAtrick Newton resumed coverage of Infinera with a Hold rating and $9 price target. He says that the company's fate is tied to its 4th generation photonic integrated circuit (PIC) + FlexCoherent processor, dubbed the Infinite Capacity Engine, which will ramp throughout 2017. Consequently, he believes that the company faces elevated execution risk.
MYGN Myriad Genetics
$19.31

0.68 (3.65%)

10/10/16
LTCO
10/10/16
DOWNGRADE
Target $16
LTCO
Sell
Myriad Genetics downgraded to Sell from Neutral at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Myriad Genetics (MYGN) to Sell citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. The analyst expects a lower growth outlook to drive "significant P/E multiple compression." Tesaro (TSRO) presented data this weekend that suggested its PARP inhibitor niraparib was active in a maintenance setting for recurrent ovarian cancer in patients with either positive or negative HRD scores. The analyst had expected the drug to benefit only HRD positive patients. As such, the use of niraparib will not require HRD testing, DeGeeter tells investors in a research note. The analyst has a $16 price target for the shares.
08/29/16
BOFA
08/29/16
NO CHANGE
BOFA
Myriad Genetics loses BCBS of Nevada contract to LabCorp, says BofA/Merrill
Analysts at BofA Merrill Lynch noted that Myriad Genetics (MYGN) has lost an in-network contract with Blue Cross Blue Shield of Nevada to LabCorp (LH) and the firm expects Myriad shares to trade down following the news. The firm sees the potential for a continuation of this trend across other BCBS systems in other states.
10/10/16
PIPR
10/10/16
NO CHANGE
PIPR
Neutral
TESARO data suggest Myriad test not necessary, says Piper Jaffray
Piper Jaffray analyst William Quirk points out that data over the weekend from TESARO (TSRO), Myriad Genetics' (MYGN) companion diagnostic partner, suggest niraparib works in all-comers, making Myriad's test not necessary. Myriad shares may be down physiologically, Quirk tells investors in a research note partially titled "When A Partnership Produces Mixed Results." The analyst, however, believes niraparib is not clinically significant in HRD negative patients and that Myriad's test will be included on the drug label. He keeps a Neutral rating on shares of Myriad. Ladenburg Thalmann this morning downgraded the stock to Neutral.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.